You may have spent the past few months thinking that companies like 23andMe or Navigenics would be a flash in the pan. But thanks to articles in major newspapers as well as video interviews all over the Internet, by now even your great-aunt Sally knows what personal genomics is. Here's a look at what all the hubbub is about.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.